Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra 11:35:07 2024-05-07 EDT 5-day change 1st Jan Change
28.13 EUR +0.93% Intraday chart for Fresenius SE & Co. KGaA +0.57% +0.21%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Strabag, Porr to Buy Portions of Fresenius' Vamed Group MT
Fresenius Hikes FY24 Outlook MT
EMEA Morning Briefing : Stock Futures Mixed as Earnings in Focus DJ
Sector Update: Health Care Stocks Advance in Late Afternoon Trading MT
Fresenius raises forecast thanks to good business at subsidiary Kabi DP
Sector Update: Health Care MT
Fresenius Medical Care Shares Decline Following Q1 Results MT
Criticism and final approval for Lufthansa course DP
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday MT
Dpa-AFX Overview: COMPANIES from 07.05.2024 - 15:15 DP
FRESENIUS SE : Deutsche Bank reiterates its Buy rating ZD
EMEA Morning Briefing : Shares Set to Gain Amid Optimism for Rate Cuts DJ
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT
FRESENIUS SE : Buy rating from Barclays ZD
FRESENIUS SE : Jefferies remains its Buy rating ZD
FRESENIUS SE : Receives a Buy rating from Berenberg ZD
Fresenius to Sell 67% of Vamed's Rehabilitation Business to PAI Partners MT
PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA. CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
FRESENIUS SE : Jefferies reiterates its Buy rating ZD
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
FRESENIUS SE : Warburg Research reiterates its Buy rating ZD
FRESENIUS SE : Goldman Sachs sticks Neutral ZD
Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA. CI
Chart Fresenius SE & Co. KGaA
More charts
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
28.13 EUR
Average target price
36.28 EUR
Spread / Average Target
+28.98%
Consensus
  1. Stock Market
  2. Equities
  3. FRE Stock
  4. News Fresenius SE & Co. KGaA
  5. Fresenius: A good ending does not allow for extreme optimism in 2024
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW